Not a single study
Story checked
Prostate Cancer: The latest in detection and treatment (opens in a new tab)
webmd.com · 2024-09-10
Short answer
Not a single studyNo clear answer.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Prostate Cancer: The latest in detection and treatment
webmd.com · 2024-09-10
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
This story isn't reporting one study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Open claim evidenceSearch result
No single source study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 10Not checkedThe article says that in recent years a number of new approaches have been developed that give doctors and patients new options to spot prostate cancer more quickly and treat it.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 10Not checkedThe article says the PSA test is not perfect: it can be abnormal in healthy men, normal in men who have prostate cancer, and it does not distinguish fast-growing cancers from slow-growing ones.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 10Not checkedThe article says studies have shown that the 4KScore test helps determine the odds of finding aggressive prostate cancer with a biopsy.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 10Not checkedThe article says the Prostate Health Index (Phi) test looks at levels of three proteins in the blood to determine the risk of finding aggressive prostate cancer if a biopsy is done.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 10Not checkedThe article says the Progensa PCA3 Assay is a urine test approved by the FDA for men 50 and over who have had one or more normal prostate biopsies but still have concerning lab tests suggesting another biopsy may be needed.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 10Not checkedThe article says Axumin, used with PET, can help detect and localize recurrent prostate cancer when PSA is elevated, and can guide decisions about biopsy and additional treatment.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 10Not checkedThe article says a recent study found that chemotherapy combined with hormone therapy helps men whose cancer has spread outside the prostate live longer.View evidenceHide evidence
As statedlive longer
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 8 of 10Not checkedThe article says several new hormone treatments have been approved by the FDA, including apalutamide, enzalutamide, and abiraterone acetate, and it briefly describes how they work.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 9 of 10Not checkedThe article says apalutamide (Erleada) is used for men with nonmetastatic, castration-resistant prostate cancer who are at high risk for spread because hormone therapy is not effective.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 10 of 10Not checkedThe article says radium-223 treats prostate cancers that have spread to the bone, lutetium Lu 177 vipivotide tetraxetan (Pluvicto) treats advanced PSMA-positive metastatic prostate cancer, and sipuleucel-T may be recommended when hormone treatment does not work and the cancer has spread outside the prostate gland.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 15 candidate papers
Comparing diagnostic prostate cancer biomarkers using a framework of clinically meaningful criteria.
BJUI Compass · 2026 · PubMed, Europe PMC
Prediction Models in Prostate Cancer Diagnosis
Prostate Cancer Diagnosis · 2013 · Crossref
Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model.
European Urology Focus · 2026 · PubMed, Europe PMC
MP77-20 AMONG MEN WITH LOW-GRADE PROSTATE CANCER ON PROSTATE BIOPSY, THE 4KSCORE PREDICTS MORE AGGRESSIVE PROSTATE CANCER AT PROSTATECTOMY.
Journal of Urology · 2015 · Crossref
Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology · 2025 · PubMed, Europe PMC
And 10 more candidates considered.